Please login to the form below
tezacaftor
This page shows the latest tezacaftor news and features for those working in and with pharma, biotech and healthcare.
Vertex’s triple combination CF therapy to become available on the NHS
The landmark deal for the combination therapy, Kaftrio (ivacaftor/tezacaftor/elexacaftor), was made possible thanks to previous negotiations between Vertex, NHS England and the UK’s National Institute for Health and ... Last October, the three parties
Latest news
-
Vertex continues upward trajectory with French Orkambi deal
The American pharma giant reached an agreement with the English regulatory bodies in October, for access to Orkambi and Vertex’s other CF treatments Symkevi (tezacaftor-ivacaftor) and Kalydeco (ivacaftor).
-
Vertex scores FDA approval for CF triple therapy Trikafta
The combination regimen of VX-445 (elexacaftor), tezacaftor and ivacaftor has been approved for CF patients aged 12 and older with one F508del mutation and one minimal function mutation and in ... and Symkevi/Symdeko (tezacaftor/ivacaftor) – which can
-
Vertex scores CF deal with Scotland, but access debate continues
Scotland to access Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor).
-
Vertex faces rejection of its CF medicines in Scotland
Another rejection over cost-effectiveness. The Scottish Medicines Consortium (SMC) has not recommended Vertex’s cystic fibrosis drugs Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor) for routine NHS use in Scotland.
-
Vertex files cystic fibrosis triple therapy with FDA
The combination regimen of VX-445 (elexacaftor), tezacaftor and ivacaftor is for CF patients aged 12 and older with one F508del mutation and one minimal function mutation and in people with ... Being able to reach a much expanded patient cohort should
More from news
Approximately 2 fully matching, plus 16 partially matching documents found.
Latest Intelligence
-
Vertex: a vision of treating all CF patients worldwide draws closer
of CF patients and now Symkevi (ivacaftor and tezacaftor). This is effective for people who have two copies of the F508del mutation plus those with one of 14 other mutations.
-
The Orkambi row explained
November 2018: Symkevi approved in Europe (tezacaftor/ivacaftor) for people with CF aged 12 and older who have two copies of F508del or one copy of F508del and one of 14
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- NHS App to revolutionise digital health and care with major digital updates by 2023
- A new era for UK-Japanese scientific research relations
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- Sanofi Global Health unveils new nonprofit Impact brand
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- A creative awakening – how pharma is bringing innovation to the patient journey
- Behaviour change – a maze of decisions influenced by personal habits, experiences and intentions
- My journey advancing the science in pulmonary hypertension
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Delivering content to fuel omnichannel engagement
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
